Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Non-Hodgkin’s Lymphoma
Drug:
IDP-023
(
NK cell stimulant
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Source:
BioSpace
Published date:
02/29/2024
Excerpt:
...today announced that the U.S. FDA has granted Fast Track designation for its lead clinical program, IDP-023, for the treatment of patients with non-Hodgkin’s lymphoma and multiple myeloma.
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login